Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
Background We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP). Methods This is an interim analysis of a dosage escalation phase 1 study in healthy 18–60-year-old volunteers in Hannover, Munich and Tübingen, Germany, and Ghent, Belgium. After giving 2 intramuscular doses of CVnCoV or placebo 28 days apart we assessed solicited local and systemic adverse events (AE) for 7 days and unsolicited AEs for 28 days after each vaccination. Immunogenicity was measured as enzyme-linked immunosorbent assay (ELISA) IgG antibodies to SARS-CoV‑2 S‑protein and receptor binding domain (RBD), and SARS-CoV‑2 neutralizing titers ($ MN_{50} $). Results In 245 volunteers who received 2 CVnCoV vaccinations (2 μg, n = 47, 4 μg, n = 48, 6 μg, n = 46, 8 μg, n = 44, 12 μg, n = 28) or placebo (n = 32) there were no vaccine-related serious AEs. Dosage-dependent increases in frequency and severity of solicited systemic AEs, and to a lesser extent local AEs, were mainly mild or moderate and transient in duration. Dosage-dependent increases in IgG antibodies to S‑protein and RBD and $ MN_{50} $ were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S‑protein or RBD, and 83% (19/23) seroconverted for $ MN_{50} $ in the 12 μg group. Responses to 12 μg were comparable to those observed in convalescent sera from known COVID-19 patients. Conclusion In this study 2 CVnCoV doses were safe, with acceptable reactogenicity and 12 μg dosages elicited levels of immune responses that overlapped those observed in convalescent sera..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
Wiener klinische Wochenschrift - 133(2021), 17-18 vom: 10. Aug., Seite 931-941 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kremsner, Peter G. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
COVID-19 |
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s00508-021-01922-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045079366 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045079366 | ||
| 003 | DE-627 | ||
| 005 | 20230520000606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210916s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00508-021-01922-y |2 doi | |
| 035 | |a (DE-627)SPR045079366 | ||
| 035 | |a (SPR)s00508-021-01922-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.60 |2 bkl | ||
| 100 | 1 | |a Kremsner, Peter G. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Background We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP). Methods This is an interim analysis of a dosage escalation phase 1 study in healthy 18–60-year-old volunteers in Hannover, Munich and Tübingen, Germany, and Ghent, Belgium. After giving 2 intramuscular doses of CVnCoV or placebo 28 days apart we assessed solicited local and systemic adverse events (AE) for 7 days and unsolicited AEs for 28 days after each vaccination. Immunogenicity was measured as enzyme-linked immunosorbent assay (ELISA) IgG antibodies to SARS-CoV‑2 S‑protein and receptor binding domain (RBD), and SARS-CoV‑2 neutralizing titers ($ MN_{50} $). Results In 245 volunteers who received 2 CVnCoV vaccinations (2 μg, n = 47, 4 μg, n = 48, 6 μg, n = 46, 8 μg, n = 44, 12 μg, n = 28) or placebo (n = 32) there were no vaccine-related serious AEs. Dosage-dependent increases in frequency and severity of solicited systemic AEs, and to a lesser extent local AEs, were mainly mild or moderate and transient in duration. Dosage-dependent increases in IgG antibodies to S‑protein and RBD and $ MN_{50} $ were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S‑protein or RBD, and 83% (19/23) seroconverted for $ MN_{50} $ in the 12 μg group. Responses to 12 μg were comparable to those observed in convalescent sera from known COVID-19 patients. Conclusion In this study 2 CVnCoV doses were safe, with acceptable reactogenicity and 12 μg dosages elicited levels of immune responses that overlapped those observed in convalescent sera. | ||
| 650 | 4 | |a S protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Reactogenicity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dose-response |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neutralizing antibodies |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mann, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Kroidl, Arne |e verfasserin |4 aut | |
| 700 | 1 | |a Leroux-Roels, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Schindler, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Gabor, Julian J. |e verfasserin |4 aut | |
| 700 | 1 | |a Schunk, Mirjam |e verfasserin |4 aut | |
| 700 | 1 | |a Leroux-Roels, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Jacobus J. |e verfasserin |4 aut | |
| 700 | 1 | |a Fendel, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Kreidenweiss, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Velavan, Thirumalaisamy P. |e verfasserin |4 aut | |
| 700 | 1 | |a Fotin-Mleczek, Mariola |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Stefan O. |e verfasserin |4 aut | |
| 700 | 1 | |a Quintini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Schönborn‑Kellenberger, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Vahrenhorst, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Verstraeten, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Alves de Mesquita, Margarida |e verfasserin |4 aut | |
| 700 | 1 | |a Walz, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Wolz, Olaf‑Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Oostvogels, Lidia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d Wien : Springer, 2003 |g 133(2021), 17-18 vom: 10. Aug., Seite 931-941 |w (DE-627)SPR006547729 |w (DE-600)2244243-1 |x 1613-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2021 |g number:17-18 |g day:10 |g month:08 |g pages:931-941 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00508-021-01922-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q ASE |
| 936 | b | k | |a 44.60 |q ASE |
| 951 | |a AR | ||
| 952 | |d 133 |j 2021 |e 17-18 |b 10 |c 08 |h 931-941 | ||